Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
HER2, a well established oncogenic member of EGFR family, is among the most intensely investigated kinase drug targets. In contrast to hotspot mutations of EGFR, few mutations of HER2 locate in activation loop within kinase domain. We previously reported the molecular mechanism underlying hyper kina...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Impact Journals LLC
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741629/ |